Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bamias

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 9